Breaking News

PPD Names Health Outcomes VP

By Kristin Brooks | March 20, 2014

Pollock to direct health outcomes and evidence-based medicine

Michael Pollock has been appointed vice president of real world outcomes at Pharmaceutical Product Development, LLC (PPD). Mr. Pollock is responsible for directing and enhancing the company’s capabilities in health outcomes and evidence-based medicine to help biopharmaceutical clients optimize market and patient access to novel therapies.
Most recently, Mr. Pollock was president of Reynolds Pollock & Associates, a health outcomes research and market access strategy consulting company. He also held roles as vice president of global health economics at Biogen Idec, vice president of sales and marketing at Elan Pharmaceuticals, vice president of sales and marketing and information services at Oncology Therapeutics Network, a division of Bristol-Myers Squibb, and director and head of worldwide health economics at Glaxo Wellcome.

“PPD is continually strengthening its offerings across the real world outcomes spectrum, and Michael brings a unique background to this role, having held senior positions both in sales and marketing, and in health economics for both large pharmaceutical and biotechnology companies,” said Rob Dow, M.D., PPD’s senior vice president of medical affairs. “He has the knowledge, experience and leadership skills to help grow PPD’s real world outcomes solutions, as we drive value and fuel success for clients.”
PPD tailors real world outcomes studies for clients aimed at providing flexible designs that meet specific objectives, marketplace needs and regulatory requirements in the post-approval environment.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important